Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sun Pharmaceutical Industries has announced that the FDA has granted approval for the abbreviated new drug application to market fosphenytoin sodium injection.
Subscribe to our email newsletter
Fosphenytoin sodium injection USP, 50mg PE/mL, is therapeutically equivalent to Parke Davis’s Cerebyx, and is available in two packs: 100mg PE/ 2mL and 500mg PE/10mL single dose vials.
Fosphenytoin sodium is used for the control of generalized convulsive status epilepticus as well as for prevention and treatment of seizures occurring during neurosurgery. This product will reach the market shortly.